Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2
Adriano Taddeo, Inês Berenguer Veiga, Christelle Devisme, R. Boss, Philippe Plattet, Sebastian Weigang, Georg Kochs, Volker Thiel, Charaf Benarafa, Gert Zimmer
Abstract
Abstract Immunization with vesicular stomatitis virus (VSV)-vectored COVID-19 vaccine candidates expressing the SARS-CoV-2 spike protein in place of the VSV glycoprotein relies implicitly on expression of the ACE2 receptor at the muscular injection site. Here, we report that such a viral vector vaccine did not induce protective immunity following intramuscular immunization of K18-hACE2 transgenic mice. However, when the viral vector was trans -complemented with the VSV glycoprotein, intramuscular immunization resulted in high titers of spike-specific neutralizing antibodies. The vaccinated animals were fully protected following infection with a lethal dose of SARS-CoV-2-S D614G via the nasal route, and partially protected if challenged with the SARS-CoV-2 Delta variant. While dissemination of the challenge virus to the brain was completely inhibited, replication in the lung with consequent lung pathology was not entirely controlled. Thus, intramuscular immunization was clearly enhanced by trans -complementation of the VSV-vectored vaccines by the VSV glycoprotein and led to protection from COVID-19, although not achieving sterilizing immunity.